Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 May 04 2016 Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results Apr 18 2016 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors Apr 11 2016 Cyclacel Announces Receipt of Nasdaq Extension Mar 24 2016 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results Mar 17 2016 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results Feb 05 2016 Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing Feb 02 2016 Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference Jan 11 2016 Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 Dec 14 2015 Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium Nov 23 2015 CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models Nov 12 2015 Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results Nov 09 2015 Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference Nov 05 2015 Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results Oct 26 2015 Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference Oct 22 2015 Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors Sep 17 2015 Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas Sep 03 2015 Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference Aug 11 2015 Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results Aug 05 2015 Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results Jul 02 2015 First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder Jun 29 2015 Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis Jun 17 2015 Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference May 12 2015 Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results May 05 2015 Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results Apr 20 2015 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 May 04 2016 Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results Apr 18 2016 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors Apr 11 2016 Cyclacel Announces Receipt of Nasdaq Extension Mar 24 2016 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results Mar 17 2016 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results Feb 05 2016 Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing Feb 02 2016 Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference Jan 11 2016 Cyclacel Reviews 2015 Achievements and Announces Key Business Objectives for 2016 Dec 14 2015 Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium Nov 23 2015 CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models Nov 12 2015 Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results Nov 09 2015 Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference Nov 05 2015 Cyclacel Pharmaceuticals to Release Third Quarter 2015 Financial Results Oct 26 2015 Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference Oct 22 2015 Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors Sep 17 2015 Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas Sep 03 2015 Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference Aug 11 2015 Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results Aug 05 2015 Cyclacel Pharmaceuticals to Release Second Quarter 2015 Financial Results Jul 02 2015 First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder Jun 29 2015 Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis Jun 17 2015 Cyclacel Pharmaceuticals to Present at 10th Annual JMP Securities Healthcare Conference May 12 2015 Cyclacel Pharmaceuticals Reports First Quarter 2015 Financial Results May 05 2015 Cyclacel Pharmaceuticals to Release First Quarter 2015 Financial Results Apr 20 2015 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last »
Apr 18 2016 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
Dec 14 2015 Molecular Basis For Development of Cyclacel's CYC065 CDK2/9 Inhibitor In Triple-Negative Breast Cancer Presented At San Antonio Breast Cancer Symposium
Nov 23 2015 CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models
Nov 09 2015 Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference
Oct 26 2015 Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference
Oct 22 2015 Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors
Sep 17 2015 Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas
Sep 03 2015 Cyclacel Pharmaceuticals to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Jul 02 2015 First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
Jun 29 2015 Cyclacel & ManRos Therapeutics Announce Licensing & Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis
Apr 20 2015 Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds
